AdaptHealth Corp. (AHCO)
NASDAQ: AHCO · Real-Time Price · USD
7.53
-0.20 (-2.59%)
At close: Nov 17, 2026, 4:00 PM EST
7.40
-0.13 (-1.73%)
After-hours: Nov 17, 2026, 7:30 PM EST
← View all transcripts

UBS Global Healthcare Conference

Nov 10, 2026

Summary

Kaiser margins improved to a 14% September exit run rate, with a 20% target by late 2027 and contract economics negotiations aimed for year-end. 2027 priorities include West Coast expansion, core-business investment, and completing the diabetes sale.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Good afternoon, everybody. Welcome day two, UBS Global Healthcare Conference. I am Kevin Caliendo, UBS Healthcare IT and Distribution Analyst, and we are very proud and happy today to have with us management team from AdaptHealth, and featuring Suzanne Foster, the CEO. Suzanne, thank you so much for joining us again this year. Maybe before we start, you want to give a quick sort of overview of the last quarter or anything else you want to talk about?

Suzanne Foster
CEO, AdaptHealth

Where we are at as a company?

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Where you are at as a company.

Suzanne Foster
CEO, AdaptHealth

Where we are today is coming out of, I think, a transformational last year, really. It was about a year ago that we announced that we were taking on a large capitated agreement with Kaiser Permanente. Happy about that, winning that RFP, and that set us on quite an adventure. As I sit here now, being we went live essentially in February, we have learned a lot.

There was a lot going into the agreement that we did not anticipate, but we have been able to prove ourselves, and we will get into it in a minute, but we are working with our partner to make sure that it is a financially viable contract and good not only for their members, but for Adapt. That has been the high, the headline of our company. Underlying that, we are coming out of two years of pruning our portfolio.

To remind anyone who is new to this story, we were a company that was a roll-up consolidator of about 150 small HME/DME companies. A couple years ago, we set out to prune parts of the portfolio that came in through all of those acquisitions so that we could become a focused sleep and respiratory business with a supportive, what we call Wellness at Home supplies business.

That work is essentially done with the completion of us selling our diabetes segment to Cardinal Health, which will happen in the first half of 2027. We are excited about getting that behind us. The last thing I would say is we have just been on this two-year journey of real operational improvement. As you can imagine, as a roll-up, we had a lot of disparity around the way we operated, and so these last couple years has been around standard work, bringing discipline and precision to kind of that service element of what we do.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Got it. Let us start with Kaiser. It has been the overriding until the ResMed stuff, but the Kaiser contract, you saw a real turnaround in the third quarter after some hiccups and delays. Some things not your fault, for sure. We understand as we have learned. But you moved in the third quarter from negative margins to positive margins. Maybe talk through a little bit, I think it was roughly 10% margin. Is that what you quoted us?

Suzanne Foster
CEO, AdaptHealth

Ended the quarter.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Ended the quarter.

Suzanne Foster
CEO, AdaptHealth

With a 14% run rate, yeah.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Exiting September at 14% rate. You have reiterated a 20% margin target by late 2027. Maybe take us through what happened, what flipped, and what are the steps that you need to get to to hit your targets? What needs to happen?

Suzanne Foster
CEO, AdaptHealth

Sure. Just real quickly on what happened. So, a fixed fee or capitated agreement in our industry, there is two essential requirements when you enter into those. One is good claims data, so you know exactly the utilization, and the second is the environment in which the referral comes over. Going up until the eve of taking over that business from an incumbent who had it for 21 years, the partnership, I think both Adapt and Kaiser thought we had our arms around that.

As it turned out, there were some fundamental flaws, not only in the utilization data, but also in the workflows of how referrals come over. Those are two buckets. When we now, with the benefit of hindsight and seeing the data from when this first initiated in 2023 to go live in 2026, we had some gaps in the data that we didn't see when I last reported in Q2.

Through the partnership, we now see all that data, and there were two things that happened. The first thing was that there was greater than expected utilization increase from the time we bid it to the time we went live, and that's what we're working on adjusting to get the right jump-off point.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Okay.

Suzanne Foster
CEO, AdaptHealth

There was also what we saw a little bit, and we've talked about this, that pent-up demand, decreased utilization a few quarters from before we took over the contract that landed on us in the first four months that we took the contract on. Service had been compressed. We sent out letters to 12 million patients and said, "We're here.

We're your new provider," and we got a lot of response. We didn't expect that. That is behind us. So, what you saw in the improvements, the financial improvements, was one, that bolus of utilization is behind us. We're renegotiating on the jump-off point, what it should be from the increased utilization from the time we bid to the time we went live. And on the cost to serve, I call it, the part around the environment, we have, through the partnership, made a lot of improvements.

We've reduced urgent orders. We've worked on what we call the cleanliness of the order, how complete it is. So, through that partnership, we've made a lot of improvements that allowed us to really get after in Q3 the labor and the OpEx, and that's how we were able to turn those margins from negative 4% to now run rating in September at 14%. It was mostly labor and OpEx that drove that. The relationship is very stable. We're in active negotiations to right-size the financial profile ahead of schedule of what we promised to the street when we didn't have all this information.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

You're in negotiations now. You've talked about this before. Is this something that could wrap up by the end of the year, or do you need 12 months of data to feel comfortable? Or is it a run rate that you-

Suzanne Foster
CEO, AdaptHealth

Yeah.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

What does this entail?

Suzanne Foster
CEO, AdaptHealth

The partnership has committed to what we're both trying to work towards, is having certainty going into the new calendar year for budgeting reasons. We are aiming to having this done by the end of the calendar year that right-sizes the financial profitability for Adapt.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Do you have downside protection too, or upside participation? Because when we thought about capitated contracts, it was at-risk. We healthcare investors hear capitated and say-

Suzanne Foster
CEO, AdaptHealth

I know

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Are you taking risk?

Suzanne Foster
CEO, AdaptHealth

Yeah.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Are there better guidelines or guidewires around where you can go with the profitability?

Suzanne Foster
CEO, AdaptHealth

Well, it's funny, because I think the at-risk language doesn't really apply to capitated agreements in our world, because the way these deals are structured is it's a fixed fee within a corridor, and the corridor protects against massive under or over-utilization. It didn't work here because we didn't have a baseline to go off of.

In this world, let's say utilization was just as we expected when we took over the contract, and let's say two years from now, all of a sudden there was a spike. We would have been protected in that case because of the corridor. The problem we got into is the data prior to go-live did not accurately reflect the actual utilization.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

The actual baseline. The baseline was off, so the corridors were not capturing what was happening.

Suzanne Foster
CEO, AdaptHealth

As soon as that is why there is a commitment on both sides. They are saying, "We got to get your jump-off point right," of course, and that is what we are working through.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Now you feel very comfortable with the baseline, and it is just a matter of identifying-

Suzanne Foster
CEO, AdaptHealth

Yeah

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

what the guidelines. Okay. The Kaiser contract was a massive lift, we know. 40 new locations, if I-

Suzanne Foster
CEO, AdaptHealth

Yes

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

have that right. Thousands of new hires. You have two newer regional capitated wins you just announced with, I think, 70,000-plus lives. Those look more like the Humana contract, right? Is this simpler, less risk? People heard this and, "Oh my God, they are still doing this. What is happening?

Suzanne Foster
CEO, AdaptHealth

Yeah. Those are just like Humana. They go on our footprint we already have.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Okay.

Suzanne Foster
CEO, AdaptHealth

You bring them in. It's just another method of which you're paid. Rather than submitting for every widget or fee-for-service, you're basically just getting a per member per month, and nothing changes in the footprint. Those come on, just like in Q1 or Q2 when we announced the expansion of Humana in Florida and Texas, without a hiccup. Right?

Those just come on. I think that was 50,000 lives, maybe more, I'm recalling. Those are things that we're equipped to do. Kaiser's an N of one, just because of the new location in California and Kaiser Hospital specific. They operate differently. When we take on a cap deal with any other payer, it's in all the hospitals across the U.S. So it normalizes. We know how to operate those.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Are margins on these deals, how do we think about them relative to corporate average? Not Kaiser necessarily.

Suzanne Foster
CEO, AdaptHealth

Yeah.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

You gave us those guidelines.

Suzanne Foster
CEO, AdaptHealth

We've said at or better.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

At or better.

Suzanne Foster
CEO, AdaptHealth

Yep, because there's less administrative costs. You don't have a sales force. You're not pushing utilization. You're just getting what the patient needs when they need it. We like them because they're predictable, cash up front, low bad debt, at or above enterprise margins.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Are there a lot of these opportunities still out there for you?

Suzanne Foster
CEO, AdaptHealth

We have a strong pipeline out there. Particularly, it's interesting, more focused on the West Coast seems to promote these more, West Coast payers. But we have a strong pipeline, and a lot of the pipeline timing has to do with just the IT integration that's required, because they're new to a lot of payers. But we do believe that this will be a growing part of our business.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Now that Kaiser is established, and I know it's not done, you're still in the issue, but will that be a leverageable asset for you now? Meaning, you have the infrastructure there. You're talking about West Coast.

Suzanne Foster
CEO, AdaptHealth

Yeah.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Kaiser is massive, so I get that there's not a lot of market share that Kaiser doesn't have in their markets, but is it a leverageable asset such that you're saying West Coast? Is there ways to-

Suzanne Foster
CEO, AdaptHealth

Yeah, sure. So, remember, the original strategic intent going after that business was we were primarily Midwest, East Coast business. We didn't have a lot of presence in the West Coast. And what this afforded us was the opportunity to stand up a West Coast operations, and really be the only national player out there.

So the strategy here was we went out and we set up 40 locations from Washington State down, like you said, hired a couple thousand people, all new fleet, got the CapEx investment in place, and the intention was that we would go grow other non-Kaiser business in that footprint. A little wrinkle happened in February of 2026 where they announced the moratorium on Medicare billing numbers, so our strategy was a little bit halted. But what that allowed us to do was to first get the operations under control.

Now that that moratorium has been lifted and we're pending our Medicare billing numbers, in the second half of 2027, that allows us to do what we call the halo effect. We can put in salespeople and go get non-Kaiser business in that footprint, because Kaiser's carrying the full load of that footprint right now. We can do that, for the most part, without any incremental investment, because there's capacity sitting there waiting.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

How meaningful is that opportunity?

Suzanne Foster
CEO, AdaptHealth

We believe it's pretty meaningful because you have, particularly in California, not really a national player. We're really the only national player right now with scale out in the West Coast. You have some regionals, but there's pockets where we could come in and take that business. Yes, they're a big payer in that region, but there still is a lot of business to go get.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Despite all of the Kaiser headlines, headaches, that you've had to deal with, organic growth was still okay. Did it affect-

Suzanne Foster
CEO, AdaptHealth

Yeah

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

the Kaiser, the effort to fix Kaiser, did that affect the rest of the company in any way, or your ability to invest, or maybe other non-

Suzanne Foster
CEO, AdaptHealth

Sure

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Kaiser-related markets?

Suzanne Foster
CEO, AdaptHealth

Yeah, our base business year to date has grown 4%, and the reason for that, really two things. This year, the storyline for all of us was get diabetes ready to sell, do the work that we got to do there. Because it's in disc ops, we couldn't take out cost. We just had to keep as is and run it so that the sale goes through. We couldn't leverage any cost out of there. To subsidize this Kaiser ramp, we basically asked the base business to subsidize it. The organic growth being double digit this year, mostly as a result of Kaiser, of course, but we said growth is good for the year, and we held on investing in the base business.

4% came with us not backfilling salespeople, not putting more respiratory therapists on the street, really just holding the line until we right-size the cost structure of our West Coast expansion. Coming into 2027, as this contract stabilizes, we now can refocus, and we'll look at this on a consolidated basis and fund where we need to elsewhere to increase the base business growth, because the end markets are strong.

We think sleep is doing well, respiratory is doing its thing, and then our Wellness at Home segment is in support of. With all of the product pruning and portfolio pruning that we did to get rid of the low-margin stuff and the stuff that we weren't really in the market, one or two market leader, we got rid of all that over the last two years. We're super focused now, and the focus has become all these different parts of the portfolio to the segments in which we sell to. That's why you've heard me talk about more capitated where it makes sense.

Our enterprise sales team, we've stood that up this year where we have a strategic accounts initiative where we're signing a handful of preferred provider agreements every quarter now with big, large health systems, and then protect our fee-for-service business.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

If I'm just thinking about this, you have Kaiser contract that year-over-year should look better. You had core growth of 4% despite not being able to really invest the way you wanted to. You have other opportunities to lever the infrastructure that's in place. I'm not asking Harriss, I'm not asking, promise. But, I mean-

Suzanne Foster
CEO, AdaptHealth

He's going to tackle me.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

No, but yeah. He is getting out of his chair. Just thinking about this, that is a pretty good setup, right? Are there any other things to think about in terms of investments? I know obviously diabetes is no longer going to be part of it, but those are all incremental above and beyond core growth opportunities.

Suzanne Foster
CEO, AdaptHealth

Yeah, it is pretty.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Is there anything I am not thinking about here?

Suzanne Foster
CEO, AdaptHealth

No, I think you have it right. 2027 for us is going to be an exciting year where West Coast expansion, as we have talked about, is going to be a priority for us. Base business investment, and then just manageable size organic growth, meaning accounts, whether it is a preferred provider agreement or more cap. But it is going to be straight down the fairway, so to speak. We are lapping a lot of those one-times. It will be true comps. This year was transformative, and one I do not think any of us want to live through again, but it definitely challenged us, but taught us a lot. 2027, all of those lessons come to be.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

The one sort of headwind, I think, is the diabetes business being sold. You had talked about there being sort of $30 million of costs that go away, but $30 million of stranded costs. Now there is not going to be any revenue associated with 30. How do we think about that? How do we model that, or how do we think about how long will that take to go away?

Suzanne Foster
CEO, AdaptHealth

Yeah, so the problem was because we were corporately allocating based on revenue, diabetes was allocated pretty heavily. There is $30 million of costs that go away, a third of that almost on day one, that do not go with the transaction, that we can just take out. Think about it like your parachute fees and just that kind of stuff. Through the course of 2027, the rest of the other two-thirds of that 30 come out. We have said publicly that that first 30 comes out within 12 months, but primarily in 2027 if the deal goes through mid Q1, let us say.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Okay.

Suzanne Foster
CEO, AdaptHealth

We will work to take out the real estate and the labor and the per drink cost, as Harriss likes to say. Those come out. The other 30, which are true stranded, those we are going to grow through over the next couple years.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

You will try to use those to lever-

Suzanne Foster
CEO, AdaptHealth

Yeah. We believe that the growth is going to be sufficient over the next couple years to grow through those 30. We'll nibble around it, and obviously we're going to continue to improve our margins and our infrastructure and drive leverage where we can, but no massive moves because we think we can offset that through growth.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

I'm guessing that's people costs.

Suzanne Foster
CEO, AdaptHealth

Yeah

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

If it's leverageable. Okay.

Suzanne Foster
CEO, AdaptHealth

Yeah.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Got it. Since Harriss joined in September, you've redeemed your highest cost senior notes. You had a delayed draw term loan. You reaffirmed your net leverage targets. These are all good things. With the diabetes proceeds, you'll be, I think, below that 2.5 or at 2.5 leverage roughly. Is that right?

Suzanne Foster
CEO, AdaptHealth

Not yet. Not when we pay. It will be at three.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Three times?

Suzanne Foster
CEO, AdaptHealth

Yeah.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

So-

Suzanne Foster
CEO, AdaptHealth

recommitting to the 2.5, but we'll take the proceeds of diabetes. That'll put us at about three, then we'll continue to use free cash flow to continue to target that 2.5 is where we want to be.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Okay. If we think about the free cash flow, at least the way we model it, you can get there pretty quickly. Do you, at that point, when you get to that target, assuming everything else is going the way you hope for, what do you do next? Is there M&A? Is there share buybacks? Should we just continue to pay down debt and be opportunistic so that you have as much leverage as you want?

Suzanne Foster
CEO, AdaptHealth

I think it's probably going to be a balance of all three. I think at 2.5, we got a healthy leverage profile. I don't know, we might want to go a little lower, but I don't think that'll fall down to maybe number 2 or 3

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Right

Suzanne Foster
CEO, AdaptHealth

as opposed to number 1. Share buybacks would be on the table, and M&A would be opportunistic. I don't see in the near term any transformative M&A required. I think that the road ahead is, we can accomplish a lot of our growth through organic. There will be opportunistic M&A, not so much from a brick-and-mortar perspective is my philosophy, but more in kind of an acquiring of patient care, meaning resupply patients that need ongoing care.

I think our footprint is pretty solid, and there may be some West Coast geography holes that we have, but it'll be sleep and respiratory. We know our resupply engine and operations is super strong, so when you can take a smaller provider and put it in our sleep resupply, patients get better care, and that's good financially for us. That would be the focus.

This industry, as everyone knows, is continuing to consolidate, but I'm not sure how much we have to be a consolidator of it and how much of it will just naturally happen. I mean, we have had the benefit of sidestepping competitive bid with the product portfolio pruning that we did, so we've sidestepped that risk. If we stay in our lane of sleep and respiratory, focused on cap enterprise and maintaining fee-for-service, I think our growth will kind of take care of itself without any kind of massive transformational M&A that we need to do in the next couple years.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

We have one public peer of yours who's struggling financially right now. What's the industry dynamic in terms of the health of your competitors, not just the one that we know about, because we know the market is incredibly fragmented, but you do have an attractive financial profile, and your leverage is not high. You are generating cash. There are benefits to being AdaptHealth in the marketplace right now relative to peers. Is that a real thing in terms of market share? Are you able to flex a little bit right now compared to the market? Do we even contemplate that as a part of the algorithm?

Suzanne Foster
CEO, AdaptHealth

Yeah. Well, I mean, where we are able to flex is the volume. As we continue to drive volume, we got some, notwithstanding last quarter's comment around one of our larger manufacturers, but we have purchasing power. We look at a lot of smaller competitors' P&Ls through diligence and such, and what we do see is that scale does matter in this industry.

Our purchasing power is one. The other one is that you have payers who are saying, "I want to consolidate the network," and they are doing it in one of two ways. They are either going, they are using us, or they are using this convener model, which we fall within network anyway, so we get the benefit of them consolidating the market and us consolidating it through just getting big accounts. That is playing in our favor.

The other thing that I do not think people recognize is one of the reasons that we have been able to stay stable in this environment is a few years back, really over the last five years, Adapt already went through all the hard work of the tech infrastructure. We are on Oracle, we are on Brightree, we have Snap, we have a Snowflake layer. That sophistication allows us more confidence in our billing, minimizes risk there. The administrative burden is lesser.

I think a lot of our peers in the industry just have not got to that point where they have used that strong technology backbone to be a mature company, and we are through that. Now, our investments are things like growth. It is not in investing in Oracle or an ERP or something like that. That is all down, that is behind us as we became a public company.

That sophistication, I think, is really helping us right now, and it allows us when we go to a customer or a big payer or even like Kaiser, "Do you have a disaster recovery plan? Do you have these things that they want to see if they are going to put all their eggs in one basket?" And we are able to say, "Yes, we do," where I do not think a lot of our competitors in this industry have that sophistication.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Yeah, good answer. Let us talk a little bit about what happened with the manufacturer. Obviously, it was shocking to everybody, and you said, finding out the last day of the quarter, and the way you found out was horrific. It seemed like things moved forward. Can you maybe give us an update on where we are with Can we use their name or not?

Suzanne Foster
CEO, AdaptHealth

You can.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

I can?

Suzanne Foster
CEO, AdaptHealth

Yes.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

ResMed. Maybe a quick 30-second synopsis of what happened and then the update, and maybe if you can even update further, because I know there were

Suzanne Foster
CEO, AdaptHealth

Sure

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

things are still in progress.

Suzanne Foster
CEO, AdaptHealth

So, yeah, it was an unfortunate situation because we have had an incredible partnership, I mean, we are up until that one moment. Sometimes things just go sideways, and so kind of in through the middle of our organization overnight, we got an announcement that our price, our rebate structure, and tiered volume pricing would be canceled, and that we would just go to a straight on all products price increase.

Obviously, that forced the parties to the table in recognition that we are important to them, but they are also very important to us. We were able to recover quickly to, within the quarter, to say, "Hey, neither one of us want this. This isn't the right thing for us." A lot of that got resolved, and we got back to normal course of business. What does normal course of business mean? That means that we have always had an annual rebate tiered structure with them, so we were able to get that back in place for the remainder of the year, and you saw the-

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

The same levels and the like?

Suzanne Foster
CEO, AdaptHealth

Yep. Well, different tiers. We negotiated a new kind of third quarter, fourth quarter, but-

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Understood

Suzanne Foster
CEO, AdaptHealth

digestible and fair to both sides.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Okay.

Suzanne Foster
CEO, AdaptHealth

With the recognition that through that period of time, like we normally would this time of year, we work on the following year. That is where we are at. It is just back to normal course of business. It was an unfortunate hiccup that, because of the timing of earnings calls, got displayed out in the public market, but it was a real risk that we also could not back away from.

In terms of the go-forward, people have asked, "Well, what does that mean?" We have never played the game of shifting share or anything like that, because we believe we sell service, they sell the clinical value. We have been able to just continue to do our thing, because everyone is playing fairly. Then you have next year, rumors of new entrants.

That is going to be an interesting dynamic that happens in the sleep space, because that has not been the case for many years. Companies like us, we have to make sure that if we get a script that is branded, we have that product. We are going to have to look at what that means in terms of managing our suppliers to make sure we have room for everybody to go out and sell their clinical value, and then we provide the product and the service.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

There was concern that the third quarter, fourth quarter dynamic resolved, but come 1/1, there would be another, like it is a different contractor. They could raise the price again dramatically. That was a fear in the marketplace. There was some question and concern around that. It does not sound like that is where we are, or?

Suzanne Foster
CEO, AdaptHealth

No, I think that No, I don't. I think there's always been that negotiation in our business. It's just a matter of what you want to sign up for in terms of price and volume. We're back to normal course of business, or we extend. That's happened in the past too, where we just say, "You know what? We like where we are today. We'll just extend that." You have that option too. I think the bigger thing is just us getting back to our normal inventory buys and CapEx as a percent of revenue, and that's what you should measure on. Really, this little hiccup's behind us.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Okay.

Suzanne Foster
CEO, AdaptHealth

And one we hope to avoid ever again.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

How does the new The other narrative was, of course, that if the new market player was coming to market, and there's been chatter or however you want to describe it, they could be coming back even in the first quarter. We don't know if that's true. Maybe you can provide us an update if you know. How does that affect negotiations with ResMed? Does it even? Do they want to guarantee a certain amount of volume now that there might be a competitor coming to market? How does that I'm guessing from your point, it helps your leverage if there's another player.

Suzanne Foster
CEO, AdaptHealth

Sure. Well, I won't speak I don't know their strategy, but two points is, I think the other player's been very forthcoming in announcing that the last piece of what they have to clear is they have to clear their injunction.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Right.

Suzanne Foster
CEO, AdaptHealth

Everything else has been resolved. As soon as that clears, they cannot forecast plan or price plan or anything until that happens. They cannot really even announce it until that is removed. I think that we all know that that is where they are at. For us, our leverage as a company, regardless of what respiratory or sleep or wherever it may be, is obviously price and volume.

The more players, the more leverage a company like ours has. At the same time, we are in negotiations now, and who knows when there will be additional players in the market. We have to make sure that we have the right terms for what we know today.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Got it. Keeping your options open is-

Suzanne Foster
CEO, AdaptHealth

Yeah

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

always a good thing.

Suzanne Foster
CEO, AdaptHealth

I have faith in our supply chain and our procurement team.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Can you remind us, prior to them falling out of the market, what your market share was, or what percentage of your business came from Philips Respironics and/or ResMed?

Suzanne Foster
CEO, AdaptHealth

Oh, before, like years ago?

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Yeah.

Suzanne Foster
CEO, AdaptHealth

Oh, I wasn't here then. We were probably

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

You made some

Suzanne Foster
CEO, AdaptHealth

we were probably whatever the market split was, because I think historically, the way to think about us, because we've never played that game, is our supplier base is typically a reflection of the market split.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Got it. Okay. It's not like you have a preference one or the other. You don't know yet.

Suzanne Foster
CEO, AdaptHealth

Not in my tenure. We have not played that game, because we think all our partners are important. We have basically held true to, if a script comes in, we service to that, and then the unbranded scripts, we call it, we have a little wiggle room there based on either patient preference or that's when maybe cost definitely comes into where we can provide the lower-cost option.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Got it. One last sort of not you question, but it affected you, was the Medline bed field action. We were a little surprised that it was a negative thing for you, but after you explained it to us, we kind of figured out why. It wasn't that you have any liability, it's just you're negatively impacted by this. Can you give us an update? Has it gotten Medline's been talking about it like it's not

Suzanne Foster
CEO, AdaptHealth

Yeah, I give them a lot of credit for talking about it and reassuring publicly that companies like us, because it's an industry problem, that they will stand behind the cost of repair, replacement. They're definitely out there saying, and have told us personally, that they have a make-whole type of attitude towards this, which is very good.

The reason we called it out was, one, you never know in these situations, and even though it's a small part of our business, but there was really two things put aside Medline. There was either that the other suppliers couldn't ramp fast enough, because not only do you have the voluntary, the field action, but they're not making them anymore. We were concerned, can the other manufacturers ramp, and can we meet the demand of replacement and new?

Now, we do have assurances from them that that demand will be met, and in fact, we have secured front of the line with them. As beds are coming off the manufacturing, we have secured front of the line, which is good. We do believe we'll be able to maintain both. And in fact,

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Is there a cost difference now for you? Or does it affect your, I mean, it's only 7% or 8% of your revenue, but

Suzanne Foster
CEO, AdaptHealth

Yeah, it's not meaningful right now, because interestingly, we had already started diversifying that supply chain before this was announced. Sometimes we did get lucky one time in 2026. But like anything, this could become an opportunity, because if we have secured front of the line, and if there is a shortage of beds and we're the ones that have them, this could be a benefit to us.

Now, can't promise that, but we've done all the right things to make sure we're prepared for this swap out, repair, and replacement while keeping up with new demand. We baked it into our fourth quarter guidance. Harriss is the philosophy of, he'll tell you, he baked it into the low end of the guide. It would be more of a timing issue. We incur upfront costs, but at this point, we got our arms around it, and we do not think it is that meaningful. It will take some muscle, but we are prepared to do that.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

They are heavy beds.

Suzanne Foster
CEO, AdaptHealth

In many ways. It is going to take some muscle. Yeah.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

When you came on, you talked a lot about how you can improve the operations of the company, investing in technology and logistics, and felt like the businesses were run like businesses were run in the 1980s. MyApp is up to 615,000 users. Your AI mask fitting tool is driving a 94% order conversion rate. How are these digital tools and others, like, how is it working? Are you happy where we are, or is there more to do here?

Suzanne Foster
CEO, AdaptHealth

Definitely more to do. We are learning fast and furious. If you just step back and say, "Where was our areas of focus?" There was kind of three parts to it. Definitely the technology, which I will come to, which MyApp is a big driver of, the AI mask fitting, our intake portal, the use of ePrescribe, all off and running, and there is definitely more to go.

We have a goal of 2 million MyApp users in the next two years. We are well on our way there. The other one was operationally. Like I talked about, all our locations kind of ran differently in standard of work. That team now is two years into their journey, and you are seeing it in the ability to use drop ship, to standardize the work, to mature our supply chain and procurement. That work is going really well. More to do.

We are still, I would call it, coming from Danaher, I would call us still in middle, like sixth grade. We are entering middle school. But, we came from kindergarten, and I think that the team there has done a tremendous job in maturing our operations. Then the third leg of that stool was our commercial team. So, two years ago, when we talked about that, our commercial team was reporting to operators.

We did not really have a standalone commercial strategy, and the way we have been able to put in quota systems, target now our caps, our capitation fee, our managed care agreements, and then also these enterprise sales, that has all been towards this go find, acquire patients, and drive chunkier, big, large prescribers as opposed to onesie-twosies. All of that work has been happening in the background.

We transformed our portfolio and took out the low margin onesie-twosie stuff. I am thrilled with where we are, and I think this year, a lot happened, and maybe too much for the market to kind of digest at once. But that is all behind us, because if you think about us going into 2027 now, we have got a stable leadership team. Harriss being the last addition of the leadership team.

Our operations has taken out massive labor and OpEx cost. Technology has helped drive that. So, if we can stabilize our KP and get that margin profitability where it needs to, that sets us out onto the West Coast expansion. The rest of the business is now just continuous improvement. There is no more big portfolio moves. There is no big transformative M&A. The end markets are strong.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Blocking and tackling.

Suzanne Foster
CEO, AdaptHealth

It's a blocking and tackling, hopefully quiet 2027. Regulatory risks are beside us. We're not threatened by competitive bid.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

Sounds like a good setup.

Suzanne Foster
CEO, AdaptHealth

It's a calming 2027.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

We wish that for you. We are out of time. Thank you so much.

Suzanne Foster
CEO, AdaptHealth

Thank you so much.

Kevin Caliendo
Healthcare IT and Distribution Analyst, UBS

This has been great. Really appreciate it.

Suzanne Foster
CEO, AdaptHealth

Thank you.